Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN

Larimar Therapeutics, Inc.

10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).
Directional improvement in mFARS, FARS-ADL, 9-HPT, MFIS vs worsening in natural history cohort after 1 year.
Anaphylaxis occurred in 7 participants (all within first 6 weeks); starting dose regimen modified; FDA agreed.
BLA submission seeking accelerated approval for nomlabofusp expected in Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.